GlassScriptPhysician profile
Cindy Hong
NPI 1689262461
$4,323.41
in general payments reported to CMS, 2019-2025
33 companies · $906 in 2025
The $906 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,068 · 2022: $730 · 2023: $855 · 2024: $765 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.67 |
| Education | $215.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $424.82 | 2021-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $402.65 | 2022-2025 | |
| Novo Nordisk INC | $335.85 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $300.81 | 2021-2025 | Repatha, Krystexxa |
| Glaxosmithkline, LLC. | $259.21 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.55 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $215.93 | 2024 | |
| Lilly USA, LLC | $208.78 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Teva Pharmaceuticals USA, INC. | $148.53 | 2021 | |
| Exact Sciences Corporation | $138.59 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.50 | 2021-2025 | Xifaxan |
| Amarin Pharma, INC. | $107.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $91.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.73 | 2021-2023 | Trintellix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $66.99 | 2021 | |
| Pfizer INC. | $48.25 | 2022-2023 | |
| Edwards Lifesciences Corporation | $47.04 | 2022-2025 | Sapien 3 Ultra Resilia |
| Inspire Medical Systems, INC. | $43.13 | 2023 | Inspire |
| Dexcom, INC. | $31.17 | 2023 | Dexcom G6 Transmitter |
| Indivior INC. | $26.85 | 2021 | |
| Abbott Laboratories | $23.47 | 2024 | Freestyle Libre 3 |
| Vbi Vaccine (Delaware) INC. | $22.36 | 2022 | |
| Mannkind Corporation | $21.80 | 2022 | |
| Tolmar, INC. | $20.03 | 2023 | |
| Paratek Pharmaceuticals, INC. | $19.55 | 2021 | |
| Averitas Pharma INC. | $19.36 | 2024 | Qutenza |
| Jazz Pharmaceuticals INC. | $19.17 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.09 | 2025 | Qelbree |
| Ultragenyx Pharmaceutical INC. | $18.71 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.41 | 2022 | |
| Ibsa Pharma INC. | $14.32 | 2021 | |
| Currax Pharmaceuticals LLC | $12.70 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.